Termin
online buchenDoctolib
Dr. Deindl Urologie

Prostatakarzinom-Zentrum

LDR Brachytherapie – Literatur

Literaturnachweise (Langzeitergebnisse LDR-Brachytherapie):

  1. Sylvester JE, Grimm PD, Blasko JC et al.: 15-Year biochemical relapse free survival in clinical stage T1-T3 prostate cancer following combined external beam radiotherapy and brachytherapy: Seattle experience. Int J Radiat Oncol Biol Phys 2007; 67:57.
  2. Potters L, Morgenstern C, Calugaru E et al.: 12-Year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer. J Urol 2005; 173: 1562.
  3. Stone NN, Stock RG and Unger P: Intermediate-term biochemical and local control following Iodine 125 brachytherapy for prostate cancer. J Urol 2005; 173: 803.
  4. Kao J, Stone NN, Lavaf A et al.: Iodine 125 monotherapy using D90 implant doses of 180 Gy or greater. Int J Radiat Oncol Biol Phys 2008; 70:96.
  5. Zelefsky MJ, Kuban DA, Levy LB et al.: Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treatment with permanent seed implantation. Int J Radiat Oncol Biol Phys 2007; 67:327.
  6. Grimm PD, Blasko JC, Sylvester JE et al.: 10-Year biochemical (prostate-specific antigen) control of prostate cancer with Jodine 125 brachytherapy. Int J Radiat Oncol Biol Phys 2001;51: 31.
  7. Martin AG, Roy J, Beaulieu L et al.: Permanent prostate implant using high activity seeds and inverse planning with fast simulated annealing algorithim: a 12-year Canadian experience. Int J Radiat Oncol Biol Phys 2007; 67: 334.
  8. Kollmeier MA, Stock RG and Stone NN: Biochemical outcomes after prostate brachytherapie with 5-year minimum follow-up: importance of patient selection and implant quality. Int J Radiat Oncol Biol Phys 2003; 57:645.
  9. Kwok Y, DiBiase SJ, Amin PP et al.: Risk group stratification in patients undergoing permanent Jodine 125 prostate brachytherapy as monotherapy. Int J Radiat Oncol Biol Phys 2002; 53:588.
  10. Stock RG, Cesaretti JA and Stone NN: Disease-specific survival following the brachytherapy management of prostate cancer. Int J Radiat Oncol Biol Phys 2006; 64:810.
  11. Dattoli M, Wallner K, True L et al.: Longterm prostate cancer control using palladium-103 brachytherapy and external beam radiotherapy in patients with a high likelihood of extracapsular cancer extension. Urology 2007; 69: 334.
  12. Merrick GS, Butler WM, Wallner KE et al.: Androgen deprivation therapy does not impact cause-specific or overall survival in high-risk prostate cancer managed with brachytherapy and supplemental external beam. Int J Radiat Oncol Biol Phys 2007; 68:34.

Prostatakarzinomreferenz:

(Diese Liste erhebt keinen Anspruch auf Vollständigkeit. Sie gilt als Datenbasis für die in der Internetseite genannten Ergebnisse. Sie gilt als Anregung auch für den medizinischen Laien, der der englischen Sprache mächtig ist, durch die angegebene Internetseite, den jeweiligen Artikel direkt, als Link, zu lesen. Damit kann aber auch eine gezielte Überprüfung der neuesten, verfügbaren wissenschaftlichen Literatur zu den einzelnen Themen erfolgen.)

  1. Abbou CC, Salomon L, Hoznek A, Antiphon P, Cicco A, Saint F, Acame W, Bellot J, Chopin DK.
    Laparoscopic radical prostatectomy: preliminary results. Urology 2000;55:630-634.
    [ Link ]
  2. Guillonneau B, Rozet F, Cathelineau X, Lay F, Barret E, Doublet JD, Baumert H, Vallancien G.
    Perioperative complications of laparoscopic radical prostatectomy: the Montsouris 3-year experience. J Urol 2002;167:51-56.
    [ Link ]
  3. Rassweiler J, Sentker L, Seemann O, Hatzinger M, Rumpelt HJ.
    Laparoscopic radical prostatectomy with the Heilbronn technique: an analysis of the first 180 cases. J Urol 2001;166:2101-2108.
    [ Link ]
  4. Holmberg L, Bill-Axelson A, Helgesen F, Salo JO, Folmerz P, Haggman M, Andersson SO, Spangberg A, Busch C, Nordling S, Palmgren J, Adami H-O, Johansson JE, Norlen BJ, for the Scandinavia Prostatic Cancer Group Study Number 4.
    A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med 2002;347:781-789.
    [ Link ]
  5. Potosky AL, Warren JL.
    Radical prostatectomy: does higher volume lead to better quality? J Natl Cancer Inst 1999;91:1906-1907.
    [ Link ]
  6. Lepor H, Nieder AM, Ferrandino MN.
    Intraoperative and postoperative complications of radical retropubic prostatectomy in a consecutive series of 1,000 cases. J Urol 2001;166:1729-1733.
    [ Link ]
  7. Boccon-Gibod L, Ravery V, Vortos D, Toublanc M, Delmas V.
    Radical prostatectomy for prostate cancer: the perineal approach increases the risk of surgically induced positive margins and capsular incisions. J Urol 1998;160:1383-1385.
    [ Link ]
  8. Weldon VE, Tavel FR, Neuwirth H, Cohen R.
    Patterns of positive specimen margins and detectable prostate specific antigen after radical perineal prostatectomy. J Urol 1995;153:1565-1569.
    [ Link ]
  9. Davidson PJ, van den Ouden D, Schröder FH.
    Radical prostatectomy: prospective assessment of mortality and morbidity. Eur Urol 1996;29:168-173.
    [ Link ]
  10. Hautmann RE, Sauter TW, Wenderoth UK.
    Radical retropubic prostatectomy: morbidity and urinary continence in 418 consecutive cases. Urology 1994;43:47-51.
    http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8116133&dopt=Abstract
  11. Murphy GP, Mettlin C, Menck H, Winchester DP, Davidson AM.
    National patterns of prostate cancer treatment by radical prostatectomy: results of a survey by the American College of Surgeons Commission on Cancer. J Urol 1994;152:1817-1819.
    http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7523727&dopt=Abstract
  12. Walsh PC, Partin AW, Epstein JI.
    Cancer control and quality of life following anatomical radical retropubic prostatectomy: results at 10 years. J Urol 1994;152:1831-1836.
    http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7523730&dopt=Abstract
  13. Huland H, Hubner D, Henke RP.
    Systemic biopsies and digital rectal examination to identify the nervesparing side for radical prostatectomy without risk of positive margin in patients with clinical stage T2, N0 prostatic carcinoma. Urology 1994;44:211-214.
    http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8048196&dopt=Abstract
  14. Corral DA, Bahnson RR.
    Survival of men with clinically localized prostate cancer detected in the eighth decade of life. J Urol 1994;151:1326-1329.
    http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8158780&dopt=Abstract
  15. Albertsen PC, Hanley JA, Gleason DF, Barry MJ.
    Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA 1998;280:975-980.
    http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9749479&dopt=Abstract
  16. Lowe BA, Listrom MB.
    Incidental carcinoma of the prostate: an analysis of the predictors of progression. J Urol 1988;140:1340-1344.
    http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=3193495&dopt=Abstract
  17. Van Poppel H, Ameye F, Oyen R, Van de Voorde W, Baert L.
    Radical prostatectomy for localized prostate cancer. Eur J Surg Oncol 1992;18:456-462.
    http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=1426296&dopt=Abstract
  18. Elgamal AA, Van Poppel HP, Van de Voorde WM, Van Dorpe JA, Oyen RH, Baert LV.
    Impalpable invisible stage T1c prostate cancer: characteristics and clinical relevance in 100 radical prostatectomy specimens – a different view. J Urol 1997;157:244-250.
    http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8976263&dopt=Abstract
  19. Oesterling JE, Suman VJ, Zincke H, Bostwick DG.
    PSA-detected (clinical stage T1c or B0) prostate cancer. Pathologically significant tumors. Urol Clin North Am 1993;20:687-693.
    http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7505977&dopt=Abstract
  20. Epstein JI, Walsh PC, Brendler CB.
    Radical prostatectomy for impalpable prostate cancer: the Johns Hopkins experience with tumors found on transurethral resection (stages T1A and T1B) and on needle biopsy (stage T1C). J Urol 1994;152:1721-1729.
    http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7523719&dopt=Abstract
  21. Sakr WA, Haas GP, Cassin BF, Pontes JE, Crissman JD.
    The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. J Urol 1993;150:379-385.
    http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8326560&dopt=Abstract
  22. Bostwick DG, Neumann R, Qian J, Cheng L.
    Reversibility of prostatic intraepithelial neoplasia: implications for chemoprevention. Eur Urol 1999;35:492-495.
    http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10325511&dopt=Abstract
  23. Epstein JI, Chan DW, Sokoll LJ, Walsh PC, Cox JL, Rittenhouse H, Wolfert R, Carter HB.
    Nonpalpable stage T1c prostate cancer: prediction of insignificant disease using free/total prostate specific antigen levels and needle biopsy findings. J Urol 1998;160:2407-2411.
    http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9817393&dopt=Abstract
  24. Partin AW, Kattan MW, Subong EN, Walsh PC, Wojno KJ, Oesterling JE, Scardino PT, Pearson JD.
    Combination of prostate-specific antigen, clinical stage and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 1997;277:1445-1451.
    http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9145716&dopt=Abstract
  25. Graversen PH, Nielsen KT, Gasser TC, Corle DK, Madsen PO.
    Radical prostatectomy versus expectant primary treatment in stages I and II prostatic cancer. A fifteen-year follow-up. Urology 1990;36:493-498.
    http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=2247914&dopt=Abstract
  26. Gibbons RP.
    Total prostatectomy for clinically localized prostatic cancer: long-term surgical results and current morbidity. NCI Monogr 1988;7:123-126.
    http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=3173498&dopt=Abstract
  27. Pound CR, Partin AW, Epstein JI, Walsh PC.
    Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control. Urol Clin North Am 1997;24:395-406.
    http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9126237&dopt=Abstract
  28. Johansson JE, Andersson SO.
    Deferred treatment in localized prostatic cancer. Acta Oncol 1991;30:221-223.
    http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=2029410&dopt=Abstract
  29. Epstein JI, Steinberg GD.
    The significance of low grade prostate cancer on needle biopsy. A radical prostatectomy study of tumor grade, volume, and stage of the biopsied and multifocal tumor. Cancer 1990;66:1927-1932.
    http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=1699655&dopt=Abstract
  30. Ohori M, Goad JR, Wheeler TM, Eastham JA, Thompson TC, Scardino PT.
    Can radical prostatectomy alter the progression of poorly differentiated prostate cancer? J Urol 1994;152:1843-1849.
    http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7523732&dopt=Abstract
  31. Van den Ouden D, Davidson PJ, Hop W, Schröder FH.
    Radical prostatectomy as monotherapy for locally advanced (stage T3) prostate cancer. J Urol 1994;151:646-651.
    http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7508523&dopt=Abstract
  32. Lerner SE, Blute ML, Zincke H.
    Extended experience with radical prostatectomy for clinical stage T3 prostate cancer: outcome and contemporary morbidity. J Urol 1995;154:1447-1452.
    http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7658555&dopt=Abstract
  33. Di Silverio F, D’Eramo G, Buscarini M, Sciarra A, Casale P, Di Nicola S, Loreto A, Seccareccia F, De Vita R.
    Gleason score, pathological stage and serum PSA levels as predictors of disease-free survival in C-D1 prostatic cancer patients submitted to radical retropubic prostatectomy. Eur Urol 1996;30:316-321.
    http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8931963&dopt=Abstract
  34. Gerber GS, Thisted RA, Chodak GW, Schröder FH, Fromüller HG, Scardino PT, Paulson DF, Middleton AW Jr, Rukstalis DB, Smith JA Jr, Ohori M, Theiss M, Schellhammer PF.
    Results of radical prostatectomy in men with locally advanced prostate cancer: multi-institutional pooled analysis. Eur Urol 1997;32:385-390.
    http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9412793&dopt=Abstract
  35. Theiss M, Langer W, Hofmockel G, Fromüller H.
    [Radical prostatectomy as primary monotherapy in capsule penetrating prostatic carcinoma. 15 years outcome.] Urologe A 1997;36:343-347. [German]
    http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9340901&dopt=Abstract
  36. Van den Ouden D, Hop W, Schröder FH.
    Progression in and survival of patients with locally advanced prostate cancer (T3) treated with radical prostatectomy as monotherapy. J Urol 1998;160:1392-1397.
    http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9751362&dopt=Abstract
  37. Van Poppel H, Goethuys H, Callewaert P, Vanuytsel L, Van de Voorde WM, Baert L.
    Radical prostatectomy can provide a cure for well-selected clinical stage T3 prostate cancer. Eur Urol 2000;38:372-379.
    http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11025373&dopt=Abstract
  38. Fallon B, Williams RD.
    Current options in the management of clinical stage C prostatic carcinoma. Urol Clin North Am 1990;17:853-866.
    http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=2219582&dopt=Abstract
  39. Bolla M, Collette L, Blank L, Warde P, Dubois JB, Mirimanoff RO, Storme G, Bernier J, Kuten A, Sternberg C, Mattelaer J, Lopez Torecilla J, Pfeffer JR, Lino Cutajar C, Zurlo A, Pierart M.
    Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomized trial. Lancet 2002;360:103-108.
    http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12126818&dopt=Abstract
  40. Van Poppel H, Ameye F, Oyen R, Van de Voorde W, Baert L.
    Accuracy of combined computerized tomography and fine needle aspiration cytology in lymph node staging of localized prostatic carcinoma. J Urol 1994;151:1310-1314.
    http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8158777&dopt=Abstract
  41. Van Poppel H, Collette L, Kirkali Z, Brausi M, Hoekstra W, Newling DW, Decoster M and members of the EORTC GU Group.
    Quality control of radical prostatectomy: a feasibility study. Eur J Cancer 2001;37:884-891.
    http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11313177&dopt=Abstract
  42.  Ghavamian R, Bergstralh EJ, Blute ML, Slezak J, Zincke H.
    Radical retropubic prostatectomy plus orchiectomy versus orchiectomy alone for pTxN+ prostate cancer: a matched comparison. J Urol 1999;161:1223-1227, discussion 1277-1228.
    http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10081874&dopt=Abstract
  43. Han M, Partin AW, Pound CR, Epstein JI, Walsh PC.
    Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am 2001;28:555-565.
    http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11590814&dopt=Abstract
  44. Catalona WJ, Smith DJ.
    5-year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer. J Urol 1994;152:1837-1842.
    http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7523731&dopt=Abstract
  45. Hull GW, Rabbani F, Abbas F, Wheeler TM, Kattan MW, Scardino PT.
    Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J Urol 2002;167:528-534.
    http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11792912&dopt=Abstract
  46. Trapasso JG, deKernion JB, Smith RB, Dorey F.
    The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy. J Urol 1994;152:1821-1825.
    http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7523728&dopt=Abstract
  47. Zincke H, Oesterling JE, Blute ML, Bergstralh EJ, Myers RP, Barrett DM.
    Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J Urol 1994;152:1850-1857.
    http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7523733&dopt=Abstract
  48. Fair WR, Aprikian A, Sogani P, Reuter V, Whitmore WF Jr.
    The role of neoadjuvant hormonal manipulation in localized prostatic cancer. Cancer 1993;71(3 Suppl):1031-1038.
    http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7679037&dopt=Abstract
  49. Oesterling JE, Andrews PE, Suman VJ, Zincke H, Myers RP.
    Preoperative androgen deprivation therapy: artificial lowering of serum prostate specific antigen without downstaging the tumour. J Urol 1993;149:779-782.
    http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7681117&dopt=Abstract
  50. Hugosson J, Abrahamsson PA, Ahlgren G, Aus G, Lundberg S, Schelin S, Schain M, Pedersen K.
    The risk of malignancy in the surgical margin at radical prostatectomy reduced almost three-fold in patients given neo-adjuvant hormone treatment. Eur Urol 1996;29:413-419.
    http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8791047&dopt=Abstract
  51. Soloway MS, Sharifi R, Wajsman Z, McLeod D, Wood DP Jr, Puras-Baez A.
    Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxM0) prostate cancer. The Lupron Depot Neoadjuvant Prostate Cancer Study Group. J Urol 1995;154:424-428.
    http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7541859&dopt=Abstract
  52. Goldenberg SL, Klotz LH, Srigley J, Jewett MA, Mador D, Fradet Y, Barkin J, Chin J, Paquin JM, Bullock MJ, Laplante S.
    Randomized, prospective, controlled study comparing radical prostatectomy alone and neoadjuvant androgen withdrawal in the treatment of localized prostate cancer. Canadian Urologic Oncology Group. J Urol 1996;156:873-877.
    http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8709351&dopt=Abstract
  53. Witjes WP, Schulman CC, Debruyne FM.
    Preliminary results of a prospective randomized study comparing radical prostatectomy versus radical prostatectomy associated with neoadjuvant hormonal combination therapy in T2-3 N0 M0 prostatic carcinoma. The European Study Group on Neoadjuvant Treatment of Prostate Cancer. Urology 1997;49(3A Suppl):65-69.
    http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9123739&dopt=Abstract
  54. Van Poppel H, De Ridder D, Elgamal AA, Van de Voorde W, Werbrouck P, Ackaert K, Oyen R, Pittomvils G, Baert L.
    Neoadjuvant hormonal therapy before radical prostatectomy decreases the number of positive surgical margins in stage T2 prostate cancer: interim results of a prospective randomized trial. The Belgian Uro-Oncological Study Group. J Urol 1995;154:429-434.
    http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7541860&dopt=Abstract
  55. Aus G, Abrahamsson PA, Ahlgren G, Hugosson J, Lundberg S, Schain M, Schelin S, Pedersen K.
    Three month neoadjuvant hormonal therapy before radical prostatectomy; a 7-year follow-up of a randomized controlled trial. BJU Int 2002;90:561-566.
    http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12230618&dopt=Abstract
  56. Soloway MS, Pareek K, Sharifi R, Wajsman Z, McLeod D, Wood DP Jr, Puras-Baez A.
    Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxM0 prostate cancer: 5-year results. The Lupron Depot Neoadjuvant Prostate Cancer Study Group. J Urol 2002;167:112-116.
    http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11743286&dopt=Abstract
  57. Schulman CC, Debruyne FM, Forster G, Selvaggi FP, Zlotta AR, Witjes WP.
    4-year follow-up results of a European prospective randomized study on neoadjuvant hormonal therapy prior to radical prostatectomy in T2-T3N0M0 prostate cancer. European Study Group on Neoadjuvant Treatment of Prostate Cancer. Eur Urol 2000;38:706-713.
    http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11111188&dopt=Abstract
  58. Van Poppel H, Ameye F, Oyen R, Van de Voorde W, Baert L.
    Neo-adjuvant hormonotherapy does not faciliate radical prostatectomy. Acta Urol Belg 1992;60:73-82.
    http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=1492636&dopt=Abstract
  59. Van Poppel H.
    Neoadjuvant hormone therapy and radical prostatectomy: the jury is still out. Eur Urol 2001;39(Suppl 1):10-14.
    http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11114595&dopt=Abstract
  60. Leibel SA, Hanks GE, Kramer S.
    Patterns of care outcome studies: results of the national practice in adenocarcinoma of the prostate. Int J Radiat Oncol Biol Phys 1984;10:401-409.
    http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=6706734&dopt=Abstract
  61. Hanks GE, Martz KL, Diamond JJ.
    The effect of dose on local control of prostate cancer. Int J Radiat Oncol Biol Phys 1988;15:1299-1305.
    http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=3198435&dopt=Abstract
  62. Hanks GE, Hanlon A, Schultheiss T, Corn B, Shipley WU, Lee WR.
    Early prostate cancer: the national results of radiation treatment from the Patterns of Care and Radiation Therapy Oncology Group studies with prospects for improvement with conformal radiation and adjuvant androgen deprivation. J Urol 1994;152:1775-1780.
    http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7523724&dopt=Abstract
  63. Fowler JE Jr, Braswell NT, Pandey P, Seaver L.
    Experience with radical prostatectomy and radiation therapy for localized prostate cancer at a Veterans Affairs Medical Center. J Urol 1995;153:1026-1031.
    http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7853550&dopt=Abstract
  64. Zietman AL, Coen JJ, Dallow KC, Shipley WU.
    The treatment of prostate cancer by conventional radiation therapy: an analysis of long-term outcome. Int J Radiat Oncol Biol Phys 1995;32:287-292.
    http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7751173&dopt=Abstract
  65. Perez CA.
    Carcinoma of the prostate: a model for management under impending health care system reform. 1994 RSNA annual oration in radiation oncology. Radiology 1995;196:309-322.
    http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7617839&dopt=Abstract
  66. Kuban DA, el-Mahdi AM, Schellhammer PF.
    Prostate-specific antigen for pretreatment prediction and posttreatment evaluation of outcome after definitive irradiation for prostate cancer. Int J Radiat Oncol Biol Phys 1995;23:307-316.
    http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7538499&dopt=Abstract
  67. Hahn P, Baral E, Cheang M, Math MC, Kostyra J, Roelss R.
    Long-term outcome of radical radiation therapy for prostatic carcinoma: 1967-1987. Int J Radiat Oncol Biol Phys 1996;34:41-47.
    http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12118564&dopt=Abstract
  68. Zagars GK, Pollack A, von Eschenbach AC.
    Prognostic factors for clinically localized prostate carcinoma: analysis of 938 patients irradiated in the prostate specific antigen era. Cancer 1997;79:1370-1380.
    http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9083160&dopt=Abstract
  69. Pollack A, Zagars GK.
    External beam radiotherapy for stage T1/T2 prostate cancer: how does it stack up? Urology 1998;51:258-264.
    http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9495708&dopt=Abstract
  70. Ritter MA, Messing EM, Shanahan TG, Potts S, Chappell RJ, Kinsella TJ.
    Prostate-specific antigen as a predictor of radiotherapy response and patterns of failure in localized prostate cancer. J Clin Oncol 1992;10:1208-1217.
    http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=1378886&dopt=Abstract
  71. D’Amico AV, Whittington R, Malkowicz SB, Schultz D.
    A method for determining a prostate-specific antigen cure after radiation therapy for clinically localized prostatic cancer. Int J Radiat Oncol Biol Phys 1995;32:473-477.
    http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7538502&dopt=Abstract
  72. Zagars GK.
    The prognostic significance of a single serum prostate-specific antigen value beyond six months after radiation therapy for adenocarcinoma of the prostate. Int J Radiat Oncol Biol Phys 1993;27:39-44.
    http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7690017&dopt=Abstract
  73. Kavadi VS, Zagars GK, Pollack
    Serum prostate-specific antigen after radiation therapy for clinically localized prostate cancer: prognostic implications. Int J Radiat Oncol Biol Phys 1994;30:279-287.
    http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7523340&dopt=Abstract
  74. Horwitz EM, Vicini FA, Ziaja EL, Dmuchowski CF, Stromberg JS, Martinez AA.
    The correlation between the ASTRO Consensus Panel definition of biochemical failure and clinical outcome for patients with prostate cancer treated with external beam irradiation. American Society of Therapeutic Radiology and Oncology. Int J Radiat Oncol Biol Phys 1998;41:267-272.
    http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9607340&dopt=Abstract
  75. Gretzer MB, Trock BJ, Han M, Walsh PC.
    A critical analysis of the interpretation of biochemical failure in surgically treated patients using the American Society for Therapeutic Radiation and Oncology criteria. J Urol 2002;168:1419-1422.
    http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12352408&dopt=Abstract
  76. Kupelian PA, Mohan DS, Lyons J, Klein EA, Reddy CA.
    Higher than standard radiation doses (> or = 72 Gy) with or without androgen deprivation in the treatment of localized prostate cancer. Int J Radiat Oncol Biol Phys 2000;46:567-574.
    http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10701735&dopt=Abstract
  77. Bagshaw MA, Cox RS, Ray GR.
    Status of radiation therapy of prostate cancer at Stanford University. NCI Monogr 1988;7:47-60.
    http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=3173503&dopt=Abstract
  78. Perez CA, Hanks GE, Leibel SA, Zietman AL, Fuks Z, Lee WR.
    Localized carcinoma of the prostate (stages T1B, T1C, T2, and T3). Review of management with external beam radiation therapy. Cancer 1993;72:3156-3173.
    http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7694785&dopt=Abstract
  79. Arcangeli G, Micheli A, Verna L, Saracino B, Arcangeli G, Giovinazzo G, D’Angelo L, Pansadoro V, Sternberg CN.
    Prognostic impact of transurethral resection on patients irradiated for localized prostate cancer. Radiother Oncol 1995;35:123-128.
    http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7569020&dopt=Abstract
  80. Zagars GK, Johnson DE, von Eschenbach AC, Hussey DH.
    Adjuvant estrogen following radiation therapy for stage C adenocarcinoma of the prostate: long-term results of a prospective randomized study. Int J Radiat Oncol Biol Phys 1988;14:1085-1091.
    http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=3133327&dopt=Abstract
  81. Laverdiere J, Gomez JL, Cusan L, Suburu ER, Diamond P, Lemay M, Candas B, Fortin A, Labrie F.
    Beneficial effect of combination hormonal therapy administered prior and following external beam radiation therapy in localized prostate cancer. Int J Radiat Oncol Biol Phys 1997;37:247-252.
    http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9069293&dopt=Abstract
  82. Lawton CA, Winter K, Murray K, Machtay M, Mesic JB, Hanks GE, Coughlin CT, Pilepich MV.Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. Int J Radiation Oncology Biol Phys 2001;49:937-946.
    http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11240234&dopt=Abstract
  83. Pilepich MV, Winter K, John MJ, Mesic JB, Sause W, Rubin P, Lawton CA, Machtay M, Grignon D.
    Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiation Oncology Biol Phys 2001;50:1243-1252.
    http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11483335&dopt=Abstract
  84. Bolla M, Collette L, Blank L, Warde P, Dubois JB, Mirimanoff R, Storme G, Bernier J, Kuten A, Sternberg C, Mattelaer J, Lopez Torecilla J, Pfeffer JR, Lino Cutajar C, Zurlo A, Pierart M.
    Long term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomized trial. Lancet 2002;360:103-106.
    http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12126818&dopt=Abstract
  85. Zelefsky MJ, Lyass O, Fuks Z, Wolfe T, Burman C, Ling CC, Leibel SA.
    Predictors of improved outcome for patients with localized prostate cancer treated with neoadjuvant androgen ablation therapy and three-dimensional conformal radiotherapy. J Clin Oncol 1998;16:3380-3385.
    http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9779716&dopt=Abstract
  86. Anderson PR, Hanlon AL, Patchefsky A, Al-Saleem T, Hanks GE.
    Perineural invasion and Gleason 7-10 tumors predict increased failure in prostate cancer patients with pretreatment PSA < 10 ng/mL treated with conformal external beam radiation therapy. Int J Radiat Oncol Biol Phys 1998;41:1087-1092.
    http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9719119&dopt=Abstract
  87. Dearnaley DP, Khoo VS, Norman AR, Meyer L, Nahum A, Tait D, Yarnold J, Horwich A.
    Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: a randomised trial. Lancet 1999;353:267-272.
    http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9929018&dopt=Abstract
  88. Hanks GE, Schultheiss TE, Hanlon AL, Hunt M, Lee WR, Epstein BE, Coia LR.
    Optimization of conformal radiation treatment of prostate cancer: report of a dose escalation study. Int J Radiat Oncol Biol Phys 1997;37:543-550.
    http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9112451&dopt=Abstract
  89. Horwitz EM, Hanlon AL, Pinover WH, Hanks GE.
    The treatment of nonpalpable PSA-detected adenocarcinoma of the prostate with 3-dimensional conformal radiation therapy. Int J Radiat Oncol Biol Phys 1998;41:519-523.
    http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9635697&dopt=Abstract
  90. Vicini FA, Abner A, Baglan KL, Kestin LL, Martinez AA.
    Defining a dose-response relationship with radiotherapy for prostate cancer: is more really better? Int J Radiation Oncol Biol Phys 2001;51:1200-1208.
    http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11728678&dopt=Abstract
  91. Zelefsky MJ, Leibel SA, Gaudin PB, Kutcher GJ, Fleshner NE, Venkatramen ES, Reuter VE, Fair WR, Ling CC, Fuks Z.
    Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys 1998;41:491-500.
    http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9635694&dopt=Abstract
  92. Anscher MS, Robertson CN, Prosnitz LR.
    Adjuvant radiotherapy for pathologic stage T3/4 adenocarcinoma of the prostate: ten-year update. Int J Radiat Oncol Biol Phys 1995;33:37-43.
    http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7543893&dopt=Abstract
  93. Petrovich Z, Lieskovsky G, Langholz B, Formenti S, Baert L, Streeter O, Skinner DG.
    Radical prostatectomy and postoperative irradiation in patients with pathological stage C (T3) carcinoma of the prostate. Int J Radiat Oncol Biol Phys 1998;40:139-147.
    http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9422570&dopt=Abstract
  94. Valicenti RK, Gomella LG, Ismail M, Strup SE, Mulholland SG, Dicker AP, Petersen RO, Newschaffer CJ.
    The efficacy of early adjuvant radiation therapy for pT3N0 prostate cancer: a matched-pair analysis. Int J Radiat Oncol Biol Phys 1999;45:53-58.
    http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10477006&dopt=Abstract
  95. Borghede G, Hedelin H, Holmang S, Johansson KA, Aldenborg F, Pettersson S, Sernbo G, Wallgren A, Mercke C.
    Combined treatment with temporary short-term high dose rate iridium-192 brachytherapy and external beam radiotherapy for irradiation of localized prostatic carcinoma. Radiother Oncol 1997;44:237-244.
    http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9380822&dopt=Abstract
  96. Khan K, Thompson W, Bush S, Stidley C.
    Transperineal percutaneous iridium-192 interstitial template implant of the prostate: results and complications in 321 patients. Int J Radiat Oncol Biol Phys 1992;22:935-939.
    http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=1555985&dopt=Abstract
  97. Kovacs G, Galalae R, Loch T, Bertermann H, Kohr P, Schneider R, Kimming B.
    Prostate preservation by combined external beam and HDR brachytherapy in nodal negative prostate cancer. Strahlenther Onkol 1999;175 (Suppl 2):87-88.
    http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10394408&dopt=Abstract
  98. Blasko J, Ragde H, Luse RW, Sylvester JE, Cavanagh W, Grimm PD.
    Should brachytherapy be considered a therapeutic option in localized prostate cancer? Urol Clin North Am 1996;23:633-650.
    http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8948417&dopt=Abstract
  99. Ragde H, Blasko JC, Grimm PD, Kenny GM, Sylvester JE, Hoak DC, Landin K, Cavanagh W.
    Interstitial iodine-125 radiation without adjuvant therapy in the treatment of clinically localized prostate carcinoma. Cancer 1997;80:442-453.
    http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9241078&dopt=Abstract
  100. Blasko JC, Grimm PD, Sylvester JE, Badiozamani KR, Hoak D, Cavanagh W.
    Palladium-103 brachytherapy for prostate carcinoma. Int J Radiat Oncol Biol Phys 2000;46:839-850.
    http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10705004&dopt=Abstract
  101. Nag S, Beyer D, Friedland J, Grimm P, Nath R.
    American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer. Int J Radiat Oncol Biol Phys 1999;44:789-799.
    http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10386635&dopt=Abstract
  102. Ash D, Flynn A, Battermann J, de Reijke T, Lavagnini P, Blank L.
    ESTRO/EAU/EORTC recommendations on permanent seed implantation for localized prostate cancer. Radiother Oncol 2000;57:315-321.
  103. Peneau M.
    [Interstitial radiotherapy and prostate cancer. Analysis of the literature. Subcommittee of Prostate Cancer of CCAFU.] Prog Urol 1999;9:440-451. [French]
    http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10434315&dopt=Abstract
  104. Crook J, Lukka H, Klotz L, Bestic N, Johnston M; Genitourinary Cancer Disease Site Group of the Cancer Care Ontario Practice Guidelines Initiative.
    Systematic overview of the evidence for brachytherapy in clinically localized prostate cancer. CMAJ 2001;164:975-981.
    http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11314451&dopt=Abstract
  105. Walsh PC.
    Physiologic basis for hormonal therapy in carcinoma of the prostate. Urol Clin N Am 1975;2:125-140.
    http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=48206&dopt=Abstract
  106. Garnick MB.
    Prostate cancer: screening, diagnosis and measurement. Ann Intern Med 1993;118:804-818.
    http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7682387&dopt=Abstract
  107. Denis L, Murphy GP.
    Overview of phase III trials on combined androgen treatment in patients with metastatic prostate cancer. Cancer 1993;72(12 Suppl):3888-3895.
    http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8252511&dopt=Abstract
  108. The Veterans Administration Co-operative Urological Research Group.
    Treatment and survival of patients with cancer of the prostate. Surg Gynecol Obstet 1967;124:1011-1017.
    http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=6022476&dopt=Abstract
  109. Murphy GP, Beckley S, Brady MF, Chu TM, deKernion JB, Dhabuwala C, Gaeta JF, Gibbons RP, Loening SA, McKiel CF, McLeod DG, Pontes JE, Prout GR, Scardino PT, Schlegel JU, Schmidt JD, Scott WW, Slack NH, Soloway MS.
    Treatment of newly diagnosed metastic prostate cancer patients with chemotherapy agents in combination with hormones versus hormones alone. Cancer 1983;51:1264-1272.
    http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=6337697&dopt=Abstract
  110. Melton LJ 3rd, Alothman KI, Achenbach SJ, O’Fallon WM, Zincke H.
    Decline in bilateral orchiectomy for prostate cancer in Olmsted county, Minnesota, 1956-2000. Mayo Clin Proc 2001;76:1199-1203.
    http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11761500&dopt=Abstract
  111. Byar DP, Corle DK.
    Hormone therapy for prostate cancer: results of the Veterans Administration Cooperative Urological Research Group studies. NCI Monogr 1988;7:165-170.
    http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=3050535&dopt=Abstract
  112. Shearer RJ, Hendry WF, Sommerville IF, Fergusson JD.
    Plasma testosterone: an accurate monitor of hormonal treatment in prostatic cancer. Br J Urol 1973;45:668-677.
    http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=4359746&dopt=Abstract
  113. Blyth B, McRae CU, Espiner EA, Nicholls MG, Conaglen JV, Gilchrist N.
    Effect of stilbestrol on sodium balance, cardiac state and renin-angiotensin-aldosterone activity in prostatic carcinoma. Br Med J 1985;291:1461-1464.
    http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=3933710&dopt=Abstract
  114. De Voogt HJ, Smith PH, Pavone-Macaluso M, de Pauw M, Suciu S and members of the EORTC-GU group.
    Cardiovascular side effects of diethylstilbestrol, cyproterone acetate, medroxyprogesterone acetate and estramustine phosphate used for the treatment of advanced prostatic cancer: results from European Organization for Research on Treatment of Cancer trials 30761 and 30762. J Urol 1986;135:303-307.
    http:/www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=2935644&dopt=Abstract
  115. Pavone-Macaluso M, de Voogt HJ, Viggiano G, Barasolo E, Lardennois B, de Pauw M, Sylvester R.
    Comparison of diethylstilbestrol, cyproterone acetate and medroxyprogesterone acetate in the treatment of advanced prostatic cancer: final analysis of a randomized phase III trial of the European Organization for Research on Treatment of Cancer Urological Group. J Urol 1986;136:624-631.
    http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=2942707&dopt=Abstract
  116. Malkowicz SB.
    The role of diethylstilbestrol in the treatment of prostate cancer. Urology 2001:58(2 Suppl 1):108-113.
    http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11502463&dopt=Abstract
  117. Seidenfeld J, Samson DJ, Hasselblad V, Aronson N, Albertsen PC, Bennett CL, Wilt TJ.
    Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis. Ann Intern Med 2000;132:566-577.
    http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10744594&dopt=Abstract
  118. Kuhn JM, Billebaud T, Navratil H, Moulonguet A, Fiet J, Grise P, Louis JF, Costa P, Husson JM, Dahan R, et al.
    Prevention of the transient adverse effects of a gonadotropin-releasing hormone analogue (buserelin) in metastatic prostatic carcinoma by administration of an antiandrogen (nilutamide). N Engl J Med 1989;321:413-418.
    http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=2503723&dopt=Abstract
  119. Oefelein MG, Cornum R.
    Failure to achieve castrate levels of testosterone during luteinizing hormone releasing hormone agonist therapy: the case for monitoring serum testosterone and a treatment decision algorithm. J Urol 2000;164:726-729.
    http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10953134&dopt=Abstract
  120. Mahler C.
    Is disease flare a problem? Cancer 1993;72(12 Suppl) :3799-3802.
    http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8252493&dopt=Abstract
  121. Bubley GJ.
    Is the flare phenomenon clinically significant? Urology 2001;58(2 Suppl 1):5-9.
    http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11502435&dopt=Abstract
  122. Haviv F, Bush EN, Knittle J, Greer J.
    LHRH antagonists. Pharm Biotechnol 1998;11:131-149.
    http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9760679&dopt=Abstract
  123. Stricker HJ.
    Luteinizing hormone-releasing hormone antagonists in prostate cancer. Urology 2001;58(2 Suppl 1):24-27.
    http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11502441&dopt=Abstract
  124. Walsh PC, DeWeese TL, Eisenberger MA.
    A structured debate: immediate versus deferred androgen suppression in prostate cancer – evidence for deferred treatment. J Urol 2001;166:508-515, discussion 515-516.
    http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11458056&dopt=Abstract
  125. Byar DP.
    Proceedings: The Veterans Administration Cooperative Urological Research Group’s studies of cancer of the prostate. Cancer 1973;32:1126-1130.
    http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=4585929&dopt=Abstract
  126. Newling DW.
    Advanced prostate cancer: immediate or deferred hormone therapy? Eur Urol 2001;39(Suppl 1):15-21.
    http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11114596&dopt=Abstract
  127. Newling DW.
    Early versus late androgen deprivation therapy in metastatic disease. Urology 2001;58(2 Suppl 1):50-55.
    http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11502448&dopt=Abstract
  128. Medical Research Council Prostate Cancer Working Party Investigators Group.
    Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. Br J Urol 1997;79:235-246.
    http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9052476&dopt=Abstract
  129. Kirk D.
    MRC study: when to continue treatment in advanced prostate cancer. Prostate Cancer Prostatic Dis 1997;1:11-15.
    http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12496927&dopt=Abstract
  130. Bolla M, Gonzalez D, Warde P, Dubois JB, Mirimanoff RO, Storme G, Bernier J, Kuten A, Sternberg C, Gil T, Colette L, Pierart M.
    Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997;337:295-300.
    http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9233866&dopt=Abstract
  131. Van den Ouden D, Tribukait B, Blom JHM, Fossa SD, Kurth KH, ten Kate FJ, Heiden T, Wang N, Schröder FH.
    Deoxyribonucleic acid ploidy of core biopsies and metastatic lymph nodes of prostate cancer patients: impact on time to progression. The European Organization for Research and Treatment of Cancer Genitourinary Group. J Urol 1993;150:400-406.
    http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8326563&dopt=Abstract
  132. Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D.
    Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with nodepositive prostate cancer. N Engl J Med 1999;341:1781-1788.
    http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10588962&dopt=Abstract
  133. Zincke H, Bergstralh EJ, Larson-Keller JJ, Farrow GM, Myers RP, Lieber MM, Barett DM, Rife CC, Gonchoroff NJ.
    Stage D1 prostate cancer treated by radical prostatectomy and adjuvant hormonal treatment. Evidence for favorable survival in patients with DNA diploid tumours. Cancer 1992;70(1 Suppl):311-323.
    http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=1600493&dopt=Abstract
  134. Rambeaud JJ.
    Intermittent complete androgen blockade in metastatic prostate cancer. Eur Urol 1999;35(Suppl 1):32-36.
    http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10081701&dopt=Abstract
  135. Wolff JM, Tunn UW.
    Intermittent androgen blockade in prostate cancer: rationale and clinical experience. Eur Urol 2000;38:365-371.
    http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11025372&dopt=Abstract
  136. Crook JM, Szumacher E, Malone S, Huan S, Segal R.
    Intermittent androgen suppression in the management of prostate cancer. Urology 1999;53:530-534.
    http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10096379&dopt=Abstract
  137. Pummer K, Schmid H, Trummer H, Augustin H, Hubmer G.
    Hormonal therapy of prostate cancer: is there any news? Urol Int 1999;63:80-85.
    http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10592494&dopt=Abstract
  138. Newling DW, Fossa SD, Tunn UW, Kurth KH, de Pauw M, Sylvester R.
    Mitomycin C versus estramustine in the treatment of hormone resistant metastatic prostate cancer: the final analysis of the European Organization for Research and Treatment of Cancer, genitourinary group prospective randomized phase II study (30865). J Urol 1993;150:1840-1844.
    http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8230517&dopt=Abstract
  139. Harris KA, Reese DM.
    Treatment options in hormone-refractory prostate cancer: current and future approaches. Drugs 2001;61:2177-2192.
    http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11772129&dopt=Abstract
  140. Heidenreich A, von Knobloch R, Hofmann R.
    Current status of cytotoxic chemotherapy in hormone refractory prostate cancer. Eur Urol 2001;39:121-130.
    http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11223670&dopt=Abstract
  141. Pont A.
    Long-term experience with high dose ketoconazole therapy in patients with D2 prostatic carcinoma. J Urol 1987;137:902-904.
    http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=2437334&dopt=Abstract
  142. Harnett DR, Raghavan D, Caterson I, Pearson B, Watt H, Teriana N, Coates A, Coorey G.
    Aminogluthethimide in advanced prostate carcinoma. Br J Urol 1987;59:323-327.
    http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=3555688&dopt=Abstract
  143. Catalona WJ.
    Management of cancer of the prostate. N Engl J Med 1994;331:996-1004.
    http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7880240&dopt=Abstract